Dupilumab/REGN668
(IL-4R Antibody)

An antibody to the receptors for interleukin-4 and interleukin-13 that is being evaluated in atopic dermatitis and eosinophilic asthma in collaboration with Sanofi.

Development Phase: Phase 2 in eosinophilic asthma and Phase 1 in atopic dermatitis.

This section discusses pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been evaluated by any regulatory authorities for the indications described in this section.